化癥散积方通过抑制TYRO3经ERK通路抑制肝癌进展
该研究探讨化癥散积方(HZSJF)抗肝癌的分子机制。方法包括免疫组化、RT-qPCR、蛋白印迹、转录组测序及细胞功能实验,并用ERK抑制剂和裸鼠皮下瘤模型验证。结果显示HZSJF抑制TYRO3表达和ERK通路激活,抑制增殖、侵袭、迁移并促进凋亡,体内抑制肿瘤生长。
要点
- HZSJF可抑制肝癌细胞TYRO3表达及ERK通路活化。
- HZSJF体外抑制肝癌细胞增殖、侵袭、迁移并促进凋亡。
- ERK抑制剂验证了ERK通路在HZSJF抗肿瘤效应中的作用。
核心结论
- HZSJF通过抑制TYRO3表达经ERK信号通路减轻肝癌进展,可能成为潜在治疗手段。
研究设计与样本
- 研究采用免疫组化、RT-qPCR和蛋白印迹分析肝癌与癌旁组织中TYRO3表达。
- 用肝癌细胞研究HZSJF调控通路,转录组测序鉴定靶基因。
- 采用EdU、YO-PRO-1/PI染色和transwell实验评估增殖、凋亡、侵袭和迁移。
- 用ERK特异性抑制剂验证通路作用,并用裸鼠皮下瘤模型进行体内验证。
主要发现
- HZSJF显著抑制TYRO3表达和ERK通路激活。
- HZSJF减少肝癌细胞增殖、侵袭和迁移,促进凋亡。
- ERK抑制剂证实ERK通路参与HZSJF的抗肿瘤效应。
- HZSJF在体内抑制肿瘤生长和TYRO3表达。
临床怎么用
- 该研究为HZSJF临床用于肝癌治疗提供了TYRO3/ERK通路的分子机制依据。
- 提示TYRO3及ERK通路可作为HZSJF抗肝癌疗效的潜在监测靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Liver cancer poses a significant global health challenge owing to its increasing incidence and associated mortality rates. Traditional Chinese Medicine (TCM) has garnered attention for its potential in oncology, with formulations such as Hua Zheng San Ji Fang (HZSJF) exhibiting antineoplastic effects. HZSJF is clinically employed in China for cancer treatment; however, its molecular mechanisms in liver cancer remain elusive. TYRO3 plays a key role in tumor progression via the ERK signaling pathway, rendering it a potential therapeutic target. However, the effect of HZSJF on TYRO3 expression and its downstream signaling in liver cancer remains unexplored. PURPOSE: This study aimed to investigate the molecular mechanisms through which HZSJF alleviates liver cancer progression, focusing on its regulation of TYRO3 and the ERK signaling pathway. METHODS: TYRO3 expression in liver cancer and para-carcinoma tissues was analyzed using immunohistochemistry, reverse transcription-quantitative PCR, and western blotting. Liver cancer cells were used to investigate HZSJF-regulated pathways. Transcriptome sequencing was used to identify HZSJF-targeted genes. Cell proliferation, apoptosis, invasion, and migration were assessed using EdU, YO-PRO-1/PI staining, and transwell assays. ERK signaling involvement was examined using a specific inhibitor and validated in vivo using subcutaneous nude mouse tumor models. RESULTS: HZSJF significantly inhibited TYRO3 expression and ERK pathway activation, reducing proliferation, invasion, and migration while promoting apoptosis. The ERK inhibitor corroborated the pathway's role in the antitumor effects of HZSJF. HZSJF suppressed tumor growth and TYRO3 expression in vivo. CONCLUSION: HZSJF alleviated liver cancer progression through the ERK signaling pathway by inhibiting TYRO3 expression, presenting a potential therapeutic approach.
引用
- Xiong Z, Sui X, Bai Y, et al. Hua Zheng San Ji Fang suppresses liver cancer progression by inhibiting TYRO3 expression via the ERK signaling pathway. Phytomedicine. 2025. PMID: 40023065. doi:10.1016/j.phymed.2025.156497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。